Cyprotex Appoints Dr Rob Elsby as Leader of Drug Transporter Team
News Mar 18, 2015
Dr Elsby is a recognised expert in the drug transporter field, as exemplified by his numerous publications including co-authoring an International Transporter Consortium (ITC) whitepaper. These publications span such areas as the validation of in vitro transporter assays, predicting clinical DDI exposure changes for statins, and the role that transporter pharmacogenetics play in mediating ethnic differences in statin exposure. Dr Elsby’s role at Cyprotex will involve leading the strategic direction of Cyprotex’s transporter based assays both in terms of new research and its client-based services.
Prior to joining Cyprotex, Dr Elsby worked within a DMPK (Drug Metabolism and Pharmacokinetics) function at AstraZeneca where, over a period of 11 years, he helped develop the internal drug transporter scientific capability both practically and strategically. During this time his expert knowledge and technical interpretation of drug transporter science was routinely used towards the provision of drug disposition and clinical DDI (drug-drug interaction) risk understanding to global discovery and development project teams.
Dr Elsby will be presenting new research performed at Cyprotex in the field of transporters at the AAPS/ITC Joint Workshop on Drug Transporters in Baltimore, USA in April 2015. The research focuses on the impact of inhibitor pre-incubation time on uptake transporter interactions in vitro.
On joining Cyprotex, Dr Elsby said “I am very excited to be joining a leading scientific team that can utilise its specialist services/expertise to fully integrate in vitro ADME, transporter and toxicity data with PBPK (physiologically based pharmacokinetic) modelling approaches towards obtaining a more holistic prediction of a molecule’s safety profile in humans.”
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer said, “We are delighted to welcome Dr Elsby to our scientific team. Rob’s experience in the extrapolation of in vitro drug transporter interactions to the clinical situation will be vital in assisting our customers in understanding the relevance of the data generated. Through expansion of its transporter capabilities, Cyprotex can now offer the full range of in vitro assays for regulatory DDI (drug-drug interaction) packages.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE